Scientists are meeting to develop a better prognostic tool for the progression of breast cancer in its early stages. Today and tomorrow, the recently established consortium of the HYPOSENS project is gathering at LEITAT’s offices in Barcelona for the project’s kick-off meeting. HYPOSENS is an H2020-funded initiative that aims to develop a widely accepted, non-invasive prognostic tool to help clinicians, especially oncologists, in assessing breast cancer progression in its early stages.
As the project coordinator, LEITAT is hosting the meeting and overseeing the organization. During the meeting, project partners will have the opportunity to meet in person after several months of preparation and begin executing this important project. Each work package will be discussed in detail to ensure that objectives are met.
The HypoSens imaging system is strategically designed to offer a non-invasive alternative to the Sentinel Lymph Node Biopsy, the current surgical procedure for breast cancer staging. With an estimated cost of €60,000 per device unit and an additional €5,000 per patient, the device offers an affordable, accurate, and easy-to-use prognostic solution for clinicians, enabling more accurate and faster diagnostics as well as personalized treatment options. The initial target of the project is metastatic breast cancer, with the potential to extend to other cancer markets, such as vulval, renal, colorectal, and gastric cancers, through the use of different tumor-targeting molecules.
With an estimated 1.7 million new cases each year, breast cancer is the most common cancer among women worldwide. The low cost of the HypoSens system will enable rapid adoption by clinicians and hospitals, leading to a significant reduction in the economic and societal burden associated with the diagnosis and treatment of cancer.
